Anthem Biosciences (NSE:ANTHEM) Total Long-Term Assets: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ANTHEM Anthem Biosciences Ltd NSE:ANTHEM
24 GF Score
Price ₹950.70
! 7 Warning Signs
View Full Analysis

What is Anthem Biosciences Total Long-Term Assets?

Anthem Biosciences NSE:ANTHEM +1.08% 24 Total Long-Term Assets is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:ANTHEM with a GF Score™ of 24/100. The stock has 7 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Anthem Biosciences's Total Long-Term Assets for the quarter that ended in Jun. 2026 was ₹0 Mil.

Anthem Biosciences Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Anthem Biosciences's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthem Biosciences Total Long-Term Assets Chart

Anthem Biosciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Total Long-Term Assets
5,255.62 6,912.91 9,165.60 13,194.13 16,261.45

Anthem Biosciences Quarterly Data
Mar22 Mar23 Mar24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 11,002.01 0.00 16,261.45 0.00
NSE:ANTHEM
24GF Score
Anthem Biosciences Ltd NSE:ANTHEM
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anthem Biosciences Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of ₹0 Mil mean?
Anthem Biosciences (NSE:ANTHEM) has a Total Long-Term Assets of ₹0 Mil as of Jun. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Anthem Biosciences and its competitors.
Is Anthem Biosciences' Total Long-Term Assets too high?
Anthem Biosciences' current Total Long-Term Assets is ₹0 Mil. Overall, Anthem Biosciences has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anthem Biosciences' Total Long-Term Assets compare to VRTX and REGN?
Anthem Biosciences' Total Long-Term Assets of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Anthem Biosciences and its competitors. Anthem Biosciences's current Total Long-Term Assets is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthem Biosciences stock overvalued right now?
Anthem Biosciences (NSE:ANTHEM) has a current Total Long-Term Assets of ₹0 Mil. The current Total Long-Term Assets is ₹0 Mil. Anthem Biosciences' overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Anthem Biosciences (NSE:ANTHEM), the current Total Long-Term Assets is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anthem Biosciences Business Description

Other Exchanges 544449:India
Address No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bangalore, KA, IND, 560 099
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
24GF Score

Get the complete analysis for NSE:ANTHEM

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹950.70
Price